Meeting
2021 ASCO Annual Meeting
Overall survival, quality of life and magnitude of clinical benefit of breast cancer drugs over the last 25 years.
Authors
J. Carlos Tapia
Hospital Sant Pau, Barcelona, Spain
J. Carlos Tapia , Aida Bujosa Rodríguez , Consolacion Molto , Arnoud J. Templeton , Daniel Shepshelovich , Hadar Goldvaser , Ignasi J. Gich Saladich , Agusti Barnadas , Eitan Amir , Ariadna Tibau
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality Improvement
Track
Quality Care/Health Services Research
Sub Track
Quality Improvement
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 6571)
DOI
10.1200/JCO.2021.39.15_suppl.6571
Abstract #
6571
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Reassessing the net health benefit (NHB) of FDA approved cancer drugs with evolution of evidence using the American Society of Clinical Oncology Value Framework (ASCO-VF).
First Author: Seanthel Delos Santos
Poster
2023 ASCO Annual Meeting
The inclusion of health-related quality of life and other patient-reported outcomes in landmark trials for Food and Drug Administration oncology drug approvals: An analysis of cancer drug approvals between 2006 and 2022.
First Author: Ademola Samuel Ojo
Poster
2022 ASCO Annual Meeting
A novel analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and provides an option for efficacy assessments that could accelerate drug approvals.
First Author: Celine Yeh
Poster
2021 ASCO Annual Meeting
Correlation between work productivity loss (WPL) and European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) domains from the MONALEESA-7 (ML-7) trial of premenopausal women with HR+/HER2- advanced breast cancer (ABC).
First Author: Debu Tripathy